Technical Analysis for VCEL - Vericel Corporation

Grade Last Price % Change Price Change
grade C 15.96 -2.44% -0.40
VCEL closed down 2.44 percent on Monday, May 20, 2019, on 1.65 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Flat Down Down
See historical VCEL trend table...

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
Stochastic Reached Oversold Weakness 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Gapped Down Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -5.34%
180 Bearish Setup Bearish Swing Setup -5.34%
Calm After Storm Range Contraction -6.34%

Older signals for VCEL ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two autologous cell therapy products in the United States, including Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. The company is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company, formerly known as Aastrom Biosciences, Inc., was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Medicine Biotechnology Biopharmaceutical Medical Specialties Stem Cells Cell Therapy Burns Knee Cartilage Severe Diseases
Is VCEL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 21.0
52 Week Low 8.95
Average Volume 571,341
200-Day Moving Average 15.9274
50-Day Moving Average 17.841
20-Day Moving Average 17.297
10-Day Moving Average 17.068
Average True Range 0.7952
ADX 18.45
+DI 16.7048
-DI 30.2146
Chandelier Exit (Long, 3 ATRs ) 16.0244
Chandelier Exit (Short, 3 ATRs ) 18.2556
Upper Bollinger Band 18.5495
Lower Bollinger Band 16.0445
Percent B (%b) -0.03
BandWidth 14.48228
MACD Line -0.3542
MACD Signal Line -0.234
MACD Histogram -0.1202
Fundamentals Value
Market Cap 523.85 Million
Num Shares 32.8 Million
EPS -1.04
Price-to-Earnings (P/E) Ratio -15.35
Price-to-Sales 2.75
Price-to-Book 10.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.63
Resistance 3 (R3) 16.67 16.49 16.52
Resistance 2 (R2) 16.49 16.32 16.47 16.48
Resistance 1 (R1) 16.23 16.22 16.14 16.18 16.44
Pivot Point 16.05 16.05 16.00 16.03 16.05
Support 1 (S1) 15.78 15.88 15.69 15.74 15.48
Support 2 (S2) 15.60 15.77 15.58 15.44
Support 3 (S3) 15.34 15.60 15.40
Support 4 (S4) 15.29